Protective CD8 T cell-mediated immunity against influenza A virus infection following influenza virus-like particle vaccination.
about
Original Antigenic Sin Response to RNA Viruses and Antiviral ImmunityOne-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge.New vaccines against influenza virus.Heterogeneity of T Cell Responses to Pandemic pH1N1 Monovalent Vaccine in HIV-Infected Pregnant WomenInduction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus HemagglutininStrategies towards universal pandemic influenza vaccines.Identification of a CD4 T-cell epitope in the hemagglutinin stalk domain of pandemic H1N1 influenza virus and its antigen-driven TCR usage signature in BALB/c miceChronic ethanol exposure selectively inhibits the influenza-specific CD8 T cell response during influenza a virus infection.Mucosal vaccines: novel strategies and applications for the control of pathogens and tumors at mucosal sites.Cross-protective efficacy of dendritic cells targeting conserved influenza virus antigen expressed by Lactobacillus plantarum.Adjusted Particle Size Eliminates the Need of Linkage of Antigen and Adjuvants for Appropriated T Cell Responses in Virus-Like Particle-Based Vaccines.Harnessing Nanoparticles for Immunomodulation and VaccinesProgress and hurdles in the development of influenza virus-like particle vaccines for veterinary useAdjuvant use of the NKT cell agonist alpha-galactosylceramide leads to enhancement of M2-based DNA vaccine immunogenicity and protective immunity against influenza A virus.The establishment of surrogates and correlates of protection: Useful tools for the licensure of effective influenza vaccines?Integrase Defective Lentiviral Vector as a Vaccine Platform for Delivering Influenza Antigens.Pathogen-Mimicking Polymeric Nanoparticles based on Dopamine Polymerization as Vaccines Adjuvants Induce Robust Humoral and Cellular Immune Responses.Novel Platforms for the Development of a Universal Influenza Vaccine.A Comprehensive Review on Equine Influenza Virus: Etiology, Epidemiology, Pathobiology, Advances in Developing Diagnostics, Vaccines, and Control Strategies
P2860
Q28066918-BCF2A690-7C54-4E01-9F7A-969574BED82FQ30355863-7B1CC765-DA00-4F61-B7F6-106B2B4F974EQ30357932-9CEEDC15-34D3-46B6-8DD1-272C3DB38464Q30378589-627E8E90-1043-4E63-ADA7-BD35A28D14D1Q30380290-D4BAC802-0E26-4D29-A377-62F5B0D4F608Q30382226-F83CB42C-8D3E-4E58-BF21-5FED78687EE5Q30387865-635A3F92-DB77-4072-9AD3-702552E7422BQ35707047-4A3D85B1-5F45-4244-AA08-819A1DB41FABQ36978334-339CD505-593A-422E-876E-930CABB48E2AQ37525971-B58C644B-1952-4123-B3E8-A51AB1D878C0Q37681112-06478FC0-B600-46FE-A925-58B5CC6CCD45Q37727724-21617DB1-9568-4D75-8820-B25B9B9FC69DQ38227184-F0CF1BEE-568F-499B-B1B8-81ABC6BDD697Q38719567-D0D02C53-CF13-4B27-B9D0-F3F8AAFCF126Q47564262-84B4791F-E3B6-4B4C-9F3A-7B99CC8EA8D6Q49829189-8854E7B5-412A-4890-B4F9-A0C799B194D0Q51534139-13D8DBB1-5A17-49D8-BDC8-A9A56141CD5AQ52599675-3BD93F21-F1A3-473C-BA13-27DFA8801D10Q56970558-084CF7AE-9F79-4744-AAC3-EAE09F71FA72
P2860
Protective CD8 T cell-mediated immunity against influenza A virus infection following influenza virus-like particle vaccination.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 24 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Protective CD8 T cell-mediated ...... rus-like particle vaccination.
@en
Protective CD8 T cell-mediated ...... rus-like particle vaccination.
@nl
type
label
Protective CD8 T cell-mediated ...... rus-like particle vaccination.
@en
Protective CD8 T cell-mediated ...... rus-like particle vaccination.
@nl
prefLabel
Protective CD8 T cell-mediated ...... rus-like particle vaccination.
@en
Protective CD8 T cell-mediated ...... rus-like particle vaccination.
@nl
P2860
P356
P1476
Protective CD8 T cell-mediated ...... rus-like particle vaccination.
@en
P2093
Emily A Hemann
Sang-Moo Kang
P2860
P304
P356
10.4049/JIMMUNOL.1300954
P407
P577
2013-07-24T00:00:00Z